CTOs on the Move

64x Bio

www.64xbio.com

 
64x Bio is transforming the future of cell and gene therapy manufacturing with high throughput discovery and design of enhanced cell lines for next-generation biomanufacturing and therapeutics.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.64xbio.com
  • 409 Illinois Street
    San Francisco, CA USA 94158
  • Phone: N/A

Executives

Name Title Contact Details

Similar Companies

Regeneron

Get in the Ideas Business. At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work together to discover, invent, and develop biopharmaceutical medicines, we`re creating whole new ways of thinking about science, manufacturing and commercialization. And whole new ways of thinking about health. So connect with us. Tell us about you. Learn more about our life-changing medicines. And join us, as we build a future we believe in. Please visit www.regeneron.com/social-media-terms for more information on how to engage with Regeneron on social media. An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. We do not interview candidates on Google Hangouts.

Turnstone Biologics

Turnstone Biologics, a privately held clinical stage biotech company, is developing breakthrough cancer immunotherapies by advancing two leading and complementary platforms that drive innate and adaptive tumor immunity, to provide benefit to the millions of cancer patients underserved by current treatment options. Turnstone`s proprietary vaccinia virus platform is engineered to drive coordinated immune activation, potent viral activity, and local expression of encoded therapeutics. The innovative TIL cell therapy platform leverages clinically validated treatment protocols and has been specifically designed to extend beyond the use of bulk TILs to enrich for the most relevant T-cells for tumor eradication, preserving broad antigen diversity and minimizing treatment times to patients. The Company has an ongoing Phase 1/2a trial in solid tumors (RAPTOR) for its leading oncolytic virus candidate, RIVAL-01, and is expecting to file an IND for the lead TIL therapy candidate, TIDAL-01, in 2021.

Sigilon

Sigilon Therapeutics’ mission is to create immune-protected, engineered human cells that restore normal physiology in a wide range of diseases without generating fibrosis or immune rejection, liberating patients from challenges associated with serious chronic diseases. We're based in Cambridge, Mass.

Olink Proteomics

Thoroughly validated, rapid, high-throughput multiplexed assays for protein biomarker discovery - high specificity & minimal sample volume requirements

Santen

Santen Inc. is a Napa, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.